ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0709

Anatomical Distribution of Mrgprd-expressing Nonpeptidergic C-fibers in the Mouse Knee
Abstract Number: 0281

ANCA in SLE: Prevalence and Predictor Factors
Abstract Number: 0060

ANCA-associated Vasculitis in Caucasian and Hispanics of the Inland Empire of Southern California
Abstract Number: 1923

Angiographic Progression of Disease in Large-Vessel Vasculitis
Abstract Number: 1333

Ankylosing Spondylitis Patients at Risk of Developing Aortic Valve Regurgitation, Need for Mandatory Echocardiography?
Abstract Number: 1016

Annual Cardiac or Orthopedic Procedure Volume in Gout versus Rheumatoid Arthritis: A National Time-trends Study
Abstract Number: 1073

Anti Melanoma Differentiation-associated Protein Gene 5 Antibody Titer Monitoring Is a Useful Indicator for Early Detection of Recurrence in Rapidly Progressive Interstitial Lung Disease Associated with Dermatomyositis
Abstract Number: 0767

Anti-acetylated Protein Antibodies in Rheumatoid Arthritis (RA): Clues for the Starting Point of Autoantibody Responses in RA
Abstract Number: 0719

Anti-adalimumab Antibodies Detection Using a Novel Peptide-based Assay in a Cohort of Pediatric Patients with Chronic Rheumatic Disorders: A Pilot Study
Abstract Number: 0758

Anti-citrullinated Protein Antibodies Are Associated with Functional Disability in Unaffected First-degree Relatives of Rheumatoid Arthritis Patients
Abstract Number: 0424

Anti-Collagen II Antibodies in Patients with Relapsing Polychondritis
Abstract Number: 1098

Anti-cortactin Autoantibodies Are Associated with Key Clinical Features in Adult Myositis but Are Rarely Present in Juvenile Myositis
Abstract Number: 1427

Anti-IL5 Therapy for Eosinophilic Granulomatosis with Polyangiitis (EGPA) – An 18 Month Follow-up Study as a Steroid Sparing Therapeutic Approach
Abstract Number: 1076

Anti-Jo1 Antibody Quantification Serve as a Prognostic Factor in Anti-synthetase Syndrom
Abstract Number: 1695

Anti-Melanoma Differentiation Associated Protein 5 (MDA5) Positive Juvenile Dermatomyositis: Focus on the Lung

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].